生命早期使用头孢曲松对小鼠后期糖脂代谢的影响及两歧双歧杆菌TMC3115的改善效果研究

Effects of ceftriaxone in early life on glucolipid metabolism of mice and alleviation effects of Bifidobacterium bifidum TMC3115

目的探究生命早期使用头孢曲松和两歧双歧杆菌TMC3115(TMC3115)对小鼠后期糖脂代谢的影响以及TMC3115可能的改善作用。方法36只2周龄雌性BALB/c小鼠随机分为空白组、抗生素组和实验组(n=12),分别以生理盐水、头孢曲松(100mg/kg)、头孢曲松(100mg/kg)+TMC3115(含菌量为109CFU/d)持续灌胃至4周龄后停止灌胃,继续喂养至16周龄。最后一周测定空腹血糖并进行口服糖耐量实验,实验结束后测定血清和肝脏的甘油三酯(TG)、总胆固醇(TC)、血清空腹胰岛素水平,并计算内脏脂体比和胰岛素抵抗指数。结果各组间体重、血糖、糖耐量、血脂和胰岛素的结果无统计学差异(P>0.05);与空白组相比,抗生素组的卵巢脂体比、肠系膜脂体比和总脂体比分别上升45.5%、35.8%和39.1%(P<0.05),而实验组与抗生素组相比无统计学差异;抗生素组的肝脏TG和TC水平与空白组相比分别升高44.4%和6.5%,而实验组的肝脏TG与抗生素组相比降低28.4%(P<0.05)。结论生命早期头孢曲松干预可引起小鼠后期脂体比和肝脏甘油三酯增加,而TMC3115可能有一定的改善作用。

Objective This study was conducted to investigate whether Bifidobacterium bifidum TMC3115(TMC3115)could alleviate abnormal glucose and lipid metabolism induced by ceftriaxone during early life.Methods A total of 36 female BALB/c mice aged two weeks were randomly divided into the control group,the antibiotic group,and the experimental group.They were respectively treated with saline,ceftriaxone(100mg/kg)with or without TMC3115(109 CFU/d)daily and stopped gavage two weeks later.Then the tested mice were observed for 12 weeks.Determination of fasting blood glucose(FBG)and oral glucose tolerance test were conducted.Total cholesterol(TC),triglyceride(TG)in serum and liver,fasting insulin in serum,and weight of abdominal adipose tissue were also determined.Furthermore,homeostasis model assessment of insulin resistance(HOMA-IR)was calculated from FBG and insulin.Results There were no significant differences in weight,FBG,glucose tolerance,serum lipids and insulin among all groups(P>0.05).The abdominal adipose tissue increased in both antibiotic and experimental groups compared to that in the control group(P<0.05).Furthermore,compared with the control group,TG and TC in liver of antibiotic group increased by 44.4%and 6.5%,respectively,and liver TG in the experimental group decreased by 28.4%compared with that in the antibiotic group(P<0.05).Conclusion The intervention by ceftriaxone in early life could lead to an increase in abdominal adipose tissue and triglyceride in the liver of mice in later life.TMC3115 might alleviate such damages caused by ceftriaxone.